We are at a breakthrough moment for Alzheimer’s disease research and drug development.
Acumen is leveraging decades of learnings to deliver treatments FOR the benefit of everyone impacted by this devastating disease.
With passion, expertise, and perseverance, we are forging a path towards innovative treatments that preserve quality time for all people impacted by Alzheimer’s and other neurodegenerative diseases.
Our founders pioneered seminal discoveries and methods to understand the role of toxic soluble amyloid beta oligomers (AβOs) in synaptic dysfunction and neurodegeneration. Today, Acumen’s leaders are leveraging critical insights to advance the company and ACU193 in the clinic and beyond.